RUNX3

Aliases:
This biomarker is also known as:
  • Oncogene AML-2
  • Runt-related transcription factor 3
  • RUNX3
  • SL3/AKV core-binding factor alpha C subunit
  • SL3-3 enhancer factor 1 alpha C subunit
  • PEA2-alpha C
  • CBF-alpha-3
  • PEBP2A3
  • Acute myeloid leukemia 2 protein
  • Core-binding factor subunit alpha-3
  • PEBP2-alpha C
  • Polyomavirus enhancer-binding protein 2 alpha C subunit
  • AML2
  • CBFA3

Description…

RUNX3 is a member of the runt domain-containing family of transcription factors. A heterodimer of this protein and a beta subunit forms a complex that binds to the core DNA sequence 5'-PYGPYGGT-3' found in a number of enhancers and promoters, and can either activate or suppress transcription. It also interacts with other transcription factors. It functions as a tumor suppressor, and the gene is frequently deleted or transcriptionally silenced in cancer. Multiple transcript variants encoding different isoforms have been found for this gene.

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Accepted
Type: Genomic
HGNC Name: RUNX3

The following organs have data associated with this biomarker…

Attributes

Phase: 3
QA State: Accepted

Overview

Esophageal adenocarcinoma risk in Barrett's esophagus is increased 30- to 125- fold versus the general population. Among all Barrett's esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.

Performance Comment

p16, RUNX3, and TMEFF2 (HPP1) display increasing methylation frequencies in Barrett's esophagus versus esophageal adenocarcinoma. These markers are being further investigated for potential utility in screening Barrett's patients likely to develop esophageal adenocarcinoma.

Supporting Study Data

The following studies/protocols provide evidence supporting RUNX3 indications for the Esophagus…

Barrett's Esophagus Methylation Profiles

We propose a nested case-control study of biomarkers in the setting of BE. By bringing together research institutions with large populations of patients with BE, we will perform a multi-center study of FISH and hypermethylation markers as possible prognostic factors in BE. The centers will select from their cohorts who have progressed to HGD or to adenocarcinoma of the esophagus ("progressors"), and who also donated samples prior to the development of cancer, when their histology was felt to be benign. These subjects will be compared to individuals who have been under endoscopic surveillance, but who have not progressed to HGD or EAC ("non-progressors"). Using this approach, we hope to identify promising markers for risk stratification in BE. We expect to be able to make successful application for a prospective study of markers identified in this case-control study.

View more about this study
Biomarker Characteristics Summary

No statistics found.

Decision Rule

PMID:15824739

Additional Study-Specific Protocols
Study-Specific Publications

No study-specific publications defined.

Study-Specific Resources

No study-specific resources defined.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

Attributes

Phase: 1
QA State: Under Review
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access to this biomarker.
Version 5.1.0